{"title":"Advanced gastric cancer with peritoneal oligometastases treated with adaptive radiotherapy and concurrent chemotherapy.","authors":"Y Hama, E Tate","doi":"10.48095/ccko2024286","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>There are no reports of concurrent chemoradiotherapy for gastric cancer with peritoneal oligometastases.</p><p><strong>Case description: </strong>A 70-year-old man with gastric cancer and peritoneal oligometastases received concurrent adaptive radiotherapy and oral S-1. After radiotherapy, S-1 was discontinued, and 2 years later the tumor had completely regressed, with no recurrence or metastasis 6 years after radiotherapy.</p><p><strong>Conclusion: </strong>Peritoneal oligometastatic gastric cancer may be a candidate for curative treatment with concurrent adaptive radiotherapy and oral S-1.</p>","PeriodicalId":35565,"journal":{"name":"Klinicka Onkologie","volume":"38 4","pages":"286-290"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Klinicka Onkologie","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.48095/ccko2024286","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Background: There are no reports of concurrent chemoradiotherapy for gastric cancer with peritoneal oligometastases.
Case description: A 70-year-old man with gastric cancer and peritoneal oligometastases received concurrent adaptive radiotherapy and oral S-1. After radiotherapy, S-1 was discontinued, and 2 years later the tumor had completely regressed, with no recurrence or metastasis 6 years after radiotherapy.
Conclusion: Peritoneal oligometastatic gastric cancer may be a candidate for curative treatment with concurrent adaptive radiotherapy and oral S-1.